CNS ProteoCarta™ Assay for Neurodegenerative Disease
Working in conjunction with the Biomarker Consortium and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) as the selected discovery partner, Caprion has developed CNS ProteoCarta™, an easily customizable and highly multiplexed mass spectrometry based assay, useful in monitoring central nervous system (CNS) proteins associated with Alzheimer’s Disease.
The CNS ProteoCarta Assay allows detection and quantification of over 100 CNS-associated proteins in human cerebral spinal fluid or plasma in a single multiplexed Multiple Reaction Monitoring (MRM) assay.
CNS ProteoCarta facilitates rapid, robust assessment of CNS proteins for potential use as biomarkers of:
- Disease diagnosis
- Patient stratification
- Disease progression
- Drug efficacy
CNS ProteoCarta™ Benefits
Caprion’s MRM-based panel for Alzheimer’s disease offers several significant advantages over other biomarker quantification methods, including:
- Highly multiplexed (142 Proteins), antibody-free assay
- Developed specifically for CSF and Plasma
- Easily & rapidly expandable
- High specificity based on peptide sequence
- Requires only a small sample volume